Catherine M. Szyman - Jun 13, 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Critical Care
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Jun 13, 2023
Transactions value $
-$245,295
Form type
4
Date filed
6/13/2023, 08:59 PM
Previous filing
May 31, 2023
Next filing
Jul 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $184K +5K +14.26% $36.75 40.1K Jun 13, 2023 Direct F1
transaction EW Common Stock Sale -$429K -5K -12.48% $85.81 35.1K Jun 13, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -5K -6.94% $0.00 67K Jun 13, 2023 Common Stock 5K $36.75 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $85.75 to $86.23 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.